Neurocrine Biosciences
NBIX
$142.70
-0.41%
Neurocrine Biosciences is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and biologic therapies for neurological, psychiatric, endocrine, and immunological disorders, with its revenue base anchored by Ingrezza (valbenazine) for tardive dyskinesia and Huntington's disease chorea, alongside Crenessity for classic congenital adrenal hyperplasia and a broader pipeline spanning endometriosis, uterine fibroids, and CNS assets. The company has evolved from a single-asset story into a multi-product, profitable neuroscience platform with roughly 2,500 employees and a market capitalization near $14.1 billion, positioning it as a mid-cap specialist that competes on clinical differentiation rather than scale against larger CNS peers. The current investor debate centers on the durability of Ingrezza growth following a February 2026 guidance reset that triggered a double-digit selloff, the strategic and financial implications of the Soleno Therapeutics acquisition (a ~$2.36 billion Q2 cash outflow) that adds a high-growth rare-disease asset but pressures near-term optics, and whether the resulting pipeline diversification justifies the stock's recent relative underperformance. With revenue growth reaccelerating to nearly 40% year-over-year in Q2 2026 and a consensus strong-buy rating, the narrative has shifted from 'growth scare' to 'execution and integration' — a setup that hinges on commercial delivery over the next several quarters.…
NBIX
Neurocrine Biosciences
$142.70
Related headlines
Investment Opinion: Should I buy NBIX Today?
Rating: Buy. The thesis is that NBIX offers a rare configuration where a profitable, 39.49% revenue-growth neuroscience platform trades at an 11.36x forward PE with a $206.81 average analyst target implying +52% upside and a unanimous strong_buy consensus (mean 1.41 across 29 analysts). The February guidance reset and Soleno integration overhang have de-rated the shares to 19.9% of their 52-week range, creating an asymmetric risk/reward for patient investors.
Supporting evidence: revenue grew 39.49% YoY to $959.0 million in Q2 2026; gross margin is 98.18% and net margin 16.73%; TTM free cash flow is $870.4 million; the PEG ratio of 0.71 and forward PE of 11.36x versus trailing 29.49x frame the stock as inexpensive if consensus EPS of $14.06 is met; and the average target of $206.81 implies +52% upside with even the low target of $150 above the current price. Debt-to-equity of 0.128 and a current ratio of 3.39 confirm a conservatively financed balance sheet.
Risks and conditions: the biggest risks are operating margin compression (15.95% in Q2 2026 versus 30.07% in Q3 2025), Ingrezza concentration highlighted by the February guidance reset, and Soleno integration execution after the $2.36 billion cash outflow. This Buy would downgrade to Hold if operating margin fails to recover above 20% by Q4 2026 or if Ingrezza growth decelerates below 20%, and to Sell if the stock breaks below the $122.14 52-week low on deteriorating fundamentals. Valuation verdict: undervalued relative to its own history (PS of 4.93x versus a 16.3x-27.9x historical band, P/FCF of 18.03x versus a 36x-140x span) and fairly valued to cheap versus peers given the growth rate.
Sign up to view all
NBIX 12-Month Price Forecast
The forward-looking view is bullish but with medium confidence because the valuation is compelling only if the margin step-up normalizes. Revenue growth of 39.49% and a PEG of 0.71 support the case that the 11.36x forward PE is a discount to growth, and the unanimous analyst range above the current price signals sentiment has overshot fundamentals. The key risk is that operating margin compression to 15.95% proves structural, which would invalidate the $14.06 EPS estimate and the forward multiple. I would upgrade to high confidence if Q3 2026 shows operating margin recovering above 20% and the stock reclaims $150, and downgrade to neutral if Ingrezza growth falls below 20% or the stock breaks $122.14.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Neurocrine Biosciences's 12-month outlook, with a consensus price target around $206.22 and implied upside of +44.5% versus the current price.
Average Target
$206.22
0 analysts
Implied Upside
+44.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$150 - $253
Analyst target range
Coverage is deep and overwhelmingly constructive: 29 analysts cover NBIX with a consensus recommendation of 'strong_buy' and a mean rating of 1.41 (where 1.0 is a strong buy), and the average target price of $206.81 implies roughly +52% upside from the current $135.71. The consensus leans firmly bullish, and the institutional ratings flow supports that stance — UBS, Citigroup, RBC Capital, Canaccord Genuity, Truist, and Wedbush all maintain Buy/Outperform ratings through the July-September 2026 period, with Morgan Stanley the notable holdout at Equal Weight. The absence of any recent downgrades despite a 20% three-month drawdown suggests analysts view the weakness as sentiment-driven rather than fundamental. The target range is wide — $150 at the low end to $253 at the high end, a spread of over 68% of the current price — which signals meaningful disagreement about the trajectory. The high target of $253 likely assumes successful Soleno integration, sustained ~30%+ Ingrezza growth, pipeline catalysts, and multiple expansion toward the forward EPS estimate of $14.06; the low target of $150, still above the current price, implies a more conservative view of margin compression from the R&D/SG&A step-up and slower new-product ramp but no outright bear case. Even the low target sits 10.5% above the current price, meaning the entire published range implies upside — a rare configuration that underscores how far sentiment has detached from analyst fundamentals, though the wide dispersion warrants caution on position sizing until the stock reclaims the $150 area.
Drowning in data?
Find the real signal!
Bulls vs Bears: NBIX Investment Factors
The bull case currently has stronger evidence: revenue reaccelerated to 39.49% YoY in Q2 2026, the forward PE of 11.36x is deeply discounted against $14.06 consensus EPS, and all 29 analysts carry targets above the current price with a $206.81 average implying +52% upside. The bear case rests on operating margin compression to 15.95% from 30.07% in Q3 2025, Ingrezza concentration risk highlighted by the February guidance reset, and a 20.58% three-month decline that has left relative strength at -23.27% versus SPY. The single most important tension is whether the R&D/SG&A step-up is a temporary investment cycle that will normalize into the $14.06 forward EPS, or a permanent margin reset that makes the forward multiple illusory — how that resolves over the next several quarters will most change the thesis.
Bullish
- Revenue reaccelerating at 39.5% YoY: Q2 2026 revenue of $959.0 million grew 39.49% year-over-year versus $687.5 million in Q2 2025, a sharp acceleration from the ~28% implied by Q4 2025 vs Q4 2024 ($805.5M vs $627.7M). The sequential climb from $805.5M in Q4 2025 to $814.5M in Q1 2026 to $959.0M in Q2 2026 shows a clear upward trajectory, supporting the case for durable Ingrezza growth plus new product contributions.
- Forward PE of 11.4x implies deep discount: The trailing PE of 29.49x collapses to a forward PE of just 11.36x against consensus EPS of $14.06, implying the market expects earnings to roughly triple. For a company compounding revenue near 40% with a 98.18% gross margin and 16.73% net margin, an 11.4x forward multiple is inexpensive if estimates are met.
- Analyst consensus strong buy, +52% upside: 29 analysts carry a consensus 'strong_buy' rating (mean 1.41) with an average target of $206.81, implying +52% upside from $135.71. Even the low target of $150 sits 10.5% above the current price, meaning the entire published range implies upside — a rare configuration that underscores how far sentiment has detached from fundamentals.
- PEG of 0.71 signals growth at discount: The PEG ratio of 0.71 suggests the stock trades at a discount to its growth rate, well below the premium multiples often assigned to CNS franchises with durable IP. The 4.93x PS and 4.15x EV/Sales are moderate for a profitable, high-growth biotech, while the 20.72x EV/EBITDA is reasonable for a company compounding revenue near 40%.
Bearish
- Operating margin compressed to 15.95%: Operating margin fell from 26.18% in Q4 2025 and 30.07% in Q3 2025 to 15.95% in Q2 2026, driven by R&D rising to $326.7 million and SG&A to $439.7 million. This deliberate investment step-up tied to pipeline and launch activity pressures near-term earnings optics even as revenue grows.
- Ingrezza concentration and guidance reset: Revenue remains anchored by Ingrezza, and the February 2026 guidance reset triggered a 10.6% single-day stock drop, a reminder that management's conservatism can whipsaw sentiment. The investor debate centers on the durability of Ingrezza growth, and any deceleration in the franchise would hit a revenue base still heavily dependent on it.
- Soleno deal consumed balance-sheet flexibility: The ~$2.36 billion Q2 cash outflow for Soleno drew cash down to $338.9 million, pressuring near-term optics and integration execution. The acquisition adds a high-growth rare-disease asset but introduces integration risk and a multi-quarter overhang until the deal proves accretive.
- Relative strength weak across every window: NBIX is down 20.58% over 3 months and 9.22% over 1 month versus SPY gains of 2.69% and 1.22%, with relative strength of -23.27% over 3 months and -16.85% over 1 year. The failure to hold the $150 area in mid-September suggests sellers remain in control near term.
NBIX Technical Analysis
NBIX is in a corrective phase within a broader range, with the stock down 1.32% over the trailing year and trading at roughly 19.9% of its 52-week range (current price $135.71 versus a 52-week low of $122.14 and high of $186.12). That positioning near the lower quartile of the annual range signals the market has de-rated the shares rather than chased momentum, and the 27.15% max drawdown confirms a meaningful peak-to-trough retracement from the July highs. The stock is not a falling knife — it sits about 11% above its 52-week low — but it is clearly in the lower half of its band, which historically has offered better risk/reward for patient buyers than for momentum traders. Recent momentum is decisively negative and diverging from the longer-term picture: the 1-month change of -9.22% and 3-month change of -20.58% contrast with a positive 6-month change of +1.85%, indicating a sharp late-summer/early-autumn rollover after the July peak near $185.50. Relative strength is weak across every window — -10.44% versus SPY over 1 month, -23.27% over 3 months, and -16.85% over 1 year — meaning the stock is losing ground to the market even as the S&P has gained 15.53% over the past year. The 3-month decline of over 20% against a 2.69% SPY gain is a clear deceleration signal, and the failure to hold the $150 area in mid-September suggests sellers remain in control near term. Key levels are well defined: support sits at the $122.14 52-week low, with the recent $135 area acting as a secondary battleground, while resistance is the $186.12 high, with intermediate supply around $150-$160 where the September breakdown occurred. A reclaim of $150 would signal stabilization, while a break below $122 would confirm a deeper downtrend and likely force another leg of de-risking. Notably, the beta of 0.40 implies the stock is roughly 60% less volatile than the market — unusual for a biotech — which argues for smaller position-sizing adjustments on the downside but also means the stock may lag in broad risk-on rallies, consistent with its weak relative strength readings.
Beta
0.40
0.40x market volatility
Max Drawdown
-27.1%
Largest decline past year
52-Week Range
$122-$186
Price range past year
Annual Return
-0.7%
Cumulative gain past year
| Period | NBIX Return | S&P 500 |
|---|---|---|
| 1m | +2.3% | -1.0% |
| 3m | -18.8% | +2.9% |
| 6m | +11.8% | +6.5% |
| 1y | -0.7% | +13.1% |
| ytd | +1.5% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NBIX Fundamental Analysis
Revenue is growing robustly and reaccelerating: Q2 2026 revenue of $959.0 million rose 39.49% year-over-year versus $687.5 million in Q2 2025, and the sequential progression from $814.5 million in Q1 2026 and $805.5 million in Q4 2025 shows a clear upward trajectory. Product revenue of $954.3 million dwarfs collaboration revenue of just $4.7 million, confirming the company is a commercial-stage operator rather than a milestone-dependent story, and the 39.5% growth rate is a marked acceleration from the roughly 28% implied by the Q4 2025 to Q4 2024 comparison ($805.5 million versus $627.7 million). The growth trend supports the investment case for a durable Ingrezza franchise plus new product contributions, though the February guidance reset is a reminder that management's conservatism can whipsaw sentiment. Profitability is solid and improving at the operating line: Q2 2026 net income was $144.4 million on a 15.06% net margin, with gross margin at 97.58% and operating margin at 15.95%, while Q1 2026 delivered $197.9 million of net income and a 24.30% net margin. Gross margins are consistently in the 97.5%-98.3% band typical of branded specialty pharma, but operating margin has compressed from 26.18% in Q4 2025 and 30.07% in Q3 2025 to 15.95% in Q2 2026, driven by R&D rising to $326.7 million and SG&A to $439.7 million — a deliberate investment step-up tied to pipeline and launch activity. The balance sheet is conservatively financed: debt-to-equity is just 0.128, the current ratio is 3.39, and TTM free cash flow is $870.4 million, while ROE of 14.71% and ROA of 11.70% are healthy for the sector. The Q2 cash flow statement shows $136.4 million of operating cash flow against $7.8 million of capex, but also a $2.36 billion acquisition outflow that drew cash down to $338.9 million — a reminder that the Soleno deal consumed balance-sheet flexibility even as recurring FCF generation remains strong enough to rebuild it.
Quarterly Revenue
$959000000.0B
2026-06
Revenue YoY Growth
+39.5%
YoY Comparison
Gross Margin
97.6%
Latest Quarter
Free Cash Flow
$870400000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NBIX Overvalued?
Because net income is positive ($144.4 million in Q2 2026), the PE ratio is the appropriate primary metric: the trailing PE is 29.49x versus a forward PE of just 11.36x, an extraordinarily wide gap that implies the market expects earnings to roughly triple. That expectation is corroborated by consensus EPS estimates of $14.06 for the forward period versus the current trailing EPS of $0.034 — a figure distorted by quarterly tax and expense timing — so the forward multiple is the more meaningful anchor and frames the stock as inexpensive if estimates are met. On a peer basis, the 4.93x PS ratio and 4.15x EV/Sales look moderate for a profitable, high-growth biotech, while the 20.72x EV/EBITDA is reasonable for a company compounding revenue near 40%; the PEG ratio of 0.71 is the standout, suggesting the stock trades at a discount to its growth rate and well below the premium multiples often assigned to CNS franchises with durable IP. The 98.18% gross margin and 16.73% net margin support a premium to the broader biotech sector, yet the current multiples do not reflect one — a disconnect that argues the market is discounting Ingrezza concentration risk and integration uncertainty. Historically, NBIX's PS ratio has ranged from roughly 16.3x to 27.9x over the past several years (including 17.75x in Q2 2026 and 27.92x in Q4 2022), and the current 4.93x reading is far below that band — though the comparison is complicated by the sharp revenue base expansion. The trailing PE of 29.49x sits mid-range versus historical readings of 16.6x-33.1x, while the price-to-free-cash-flow ratio of 18.03x is near the low end of its historical 36x-140x span, suggesting the stock is priced for pessimism rather than optimism relative to its own history.
PE
29.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~100x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin compression and revenue concentration. Operating margin fell to 15.95% in Q2 2026 from 30.07% in Q3 2025 as R&D rose to $326.7 million and SG&A to $439.7 million, and if this step-up persists, the $14.06 forward EPS that anchors the 11.36x forward PE could prove unreachable. Revenue remains anchored by Ingrezza, and the February 2026 guidance reset that triggered a 10.6% single-day drop shows how sensitive the stock is to franchise growth expectations. The $2.36 billion Soleno acquisition drew cash to $338.9 million, reducing balance-sheet flexibility even though debt-to-equity of 0.128 and TTM FCF of $870.4 million keep the financial position sound.
Market and competitive risks include valuation compression and relative underperformance. The stock trades at 4.93x PS and 29.49x trailing PE, and while these are moderate versus history (PS has ranged 16.3x-27.9x), the market is clearly discounting Ingrezza concentration and integration uncertainty. Relative strength is negative across every window — -10.44% versus SPY over 1 month, -23.27% over 3 months, and -16.85% over 1 year — and the beta of 0.40 means the stock is roughly 60% less volatile than the market, so it may lag in broad risk-on rallies. Competitive disruption in tardive dyskinesia and Huntington's chorea, plus regulatory and reimbursement headwinds for new launches like Crenessity, could further pressure the multiple.
Worst-case scenario: Ingrezza growth decelerates sharply, the Soleno integration stumbles, and the R&D/SG&A step-up proves permanent, forcing analysts to cut the $14.06 forward EPS estimate. In that chain, the stock would retest its 52-week low of $122.14, a decline of about -10% from the current $135.71, and a break below that level would confirm a deeper downtrend toward the $110-$115 area, implying roughly -15% to -19% downside. The 27.15% max drawdown already experienced from the July high near $185.50 shows the stock can shed more than a quarter of its value in a sentiment-driven de-rating, so a realistic adverse case is a -15% to -20% move from current levels.
FAQ
Ranked by severity: first, financial risk from operating margin compression to 15.95% in Q2 2026 from 30.07% in Q3 2025, which could invalidate the $14.06 forward EPS if the R&D/SG&A step-up is permanent. Second, company-specific concentration risk in Ingrezza, highlighted by the February 2026 guidance reset that triggered a 10.6% single-day drop. Third, integration risk from the $2.36 billion Soleno acquisition, which drew cash to $338.9 million and pressures near-term optics. Fourth, market risk from relative underperformance — -23.27% versus SPY over 3 months — and a beta of 0.40 that may cause the stock to lag in broad risk-on rallies. A break below the $122.14 52-week low would confirm the deepest downside scenario.
The 12-month forecast has three scenarios: a 30% probability bull case targeting $206-$253 on successful Soleno integration and margin recovery, a 50% probability base case targeting $150-$207 on consensus revenue of $5.63 billion and margin stabilization in the high-teens, and a 20% probability bear case targeting $122-$150 on Ingrezza deceleration and a permanent margin reset. The base case is most likely, with the key assumption being that operating margin recovers to 18-20% by Q4 2026 and consensus EPS of $14.06 is met. The analyst average target of $206.81 aligns with the upper end of the base case, while the low target of $150 marks the bear-case ceiling.
NBIX appears undervalued relative to its own history and fairly valued to cheap versus peers. The PS ratio of 4.93x is far below its historical 16.3x-27.9x band, the P/FCF of 18.03x is near the low end of its 36x-140x historical span, and the trailing PE of 29.49x sits mid-range versus 16.6x-33.1x history. The forward PE of 11.36x against $14.06 consensus EPS implies the market expects earnings to roughly triple, a discount that reflects Ingrezza concentration and integration uncertainty rather than fundamentals. The PEG of 0.71 suggests the market is paying less than the growth rate, implying expectations for margin normalization and successful Soleno integration are not fully priced in.
From a risk/reward perspective, NBIX screens favorably: the average analyst target of $206.81 implies +52% upside, the forward PE of 11.36x is inexpensive against 39.49% revenue growth, and even the low target of $150 sits above the current $135.71. The biggest downside risk is a retest of the $122.14 52-week low, roughly -10% from current levels, giving an asymmetric setup of about 5:1 upside to downside at the analyst average. However, the operating margin compression to 15.95% and the Soleno integration overhang mean the thesis depends on execution over the next several quarters. It is a good buy for patient investors with a 12-18 month horizon who can tolerate a possible retest of $122, and less suited for momentum traders given the -20.58% three-month decline.
NBIX is better suited for long-term holding than short-term trading. The beta of 0.40 means the stock is roughly 60% less volatile than the market, which limits short-term trading opportunities, while the negative momentum (-9.22% over 1 month, -20.58% over 3 months) makes near-term entry timing difficult. The lack of a dividend (payout ratio of 0) means returns depend entirely on price appreciation and earnings delivery, favoring a 12-18 month minimum holding period through the Soleno integration and margin normalization cycle. Earnings visibility is moderate given the February guidance reset, so a staged entry near the $122-$135 support zone with a long-term horizon is more appropriate than a short-term momentum trade.